Management of Non-Specific Unilateral Lymphadenopathy

Initial Diagnostic Approach

The National Comprehensive Cancer Network recommends performing fine-needle aspiration (FNA) as the initial diagnostic approach for nodes <4 cm, and if negative, confirm with excisional biopsy or careful surveillance over 3-4 weeks, as 30-50% of palpable inguinal lymphadenopathy is inflammatory rather than malignant 1, 2
For nodes <4 cm, the American College of Surgeons suggests that FNA is the standard initial approach, with a follow-up excisional biopsy if FNA is negative 1, 2

For nodes ≥4 cm, the National Comprehensive Cancer Network recommends treating as potentially bulky disease requiring more aggressive evaluation, and considering imaging (CT or MRI) to assess extent, location, and relationship to surrounding structures before biopsy 1, 2, 3

The National Comprehensive Cancer Network suggests that CT abdomen and pelvis with IV contrast is the preferred imaging modality when nodes are borderline enlarged or difficult to assess clinically, with a sensitivity of 58-60% for detecting metastases in normal-sized nodes 1, 2
The American College of Radiology recommends using CT to assess extent, location, and relationship to surrounding structures before biopsy, especially when there is concern for deeper pelvic or retroperitoneal involvement 2

The National Comprehensive Cancer Network recommends excisional biopsy as the gold standard when definitive diagnosis is needed, as it provides the most tissue for pathologic evaluation, while FNA is appropriate for initial evaluation but may require confirmation if negative 1, 2

The American College of Surgeons recommends clinical examination of the affected region every 3 months for confirmed reactive lymphadenopathy after negative biopsy, with re-biopsy if nodes enlarge or new systemic symptoms develop 1